Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Dapagliflozin
Related studies linked through entity extraction aliases.
Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension
- Status
- COMPLETED
- Phase
- PHASE4
Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes
- Status
- COMPLETED
- Phase
- PHASE1
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
- Status
- COMPLETED
- Phase
- PHASE3
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
- Status
- COMPLETED
- Phase
- PHASE4
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
- Status
- COMPLETED
- Phase
- PHASE4
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
- Status
- COMPLETED
- Phase
- PHASE4
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
- Status
- RECRUITING
- Phase
- NA
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
- Status
- COMPLETED
- Phase
- NA
Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
- Status
- COMPLETED
- Phase
- PHASE4
Effect of Anti-diabetic Drugs on Glycemic Variability
- Status
- COMPLETED
- Phase
- PHASE4
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
- Status
- COMPLETED
- Phase
- PHASE4
Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.
- Status
- TERMINATED
- Phase
- PHASE4
HbA1c Variability in Type II Diabetes
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy
- Status
- COMPLETED
- Phase
- PHASE4
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
- Status
- COMPLETED
- Phase
- PHASE4
A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes
- Status
- COMPLETED
- Phase
- PHASE4
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
- Status
- COMPLETED
- Phase
- PHASE3
Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2
- Status
- UNKNOWN
- Phase
- PHASE4
Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
- Status
- WITHDRAWN
- Phase
- PHASE4